Company / Total Debt
BridgeBio Pharma, Inc. Total Debt History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$2.0B
FY2025
5-year range
$430.8M / $2.0B
FY2021-FY2025
Trend
+359.0%
vs FY2024
Sector context
#21 of 83
Health Care
What the data says
Total Debt changed +359% YoY in FY2025, a notable deviation from the 7-year average annual change of +113%.
Based on SEC 10-K filings.
$2.0B in FY2025 with a 5-year CAGR of +84.5%. Top quartile in the Health Care sector.
Increased from $446M to $2.0B over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- +67.0%
- 5-Year CAGR
- +84.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 83This company $2.0B Sector average $6.2B
▼
-67.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +84.5%, indicating consistent growth.
- In FY2025, total debt increased 359.0% year-over-year.
- Ranks #21 out of 83 companies in the Health Care sector.
- Lowest total debt in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.0B | +359.0% |
| FY2024 | $437.3M | -2.0% |
| FY2023 | $446.4M | +3.6% |
| FY2022 | $431.0M | +0.1% |
| FY2021 | $430.8M | +358.8% |
| FY2020 | $93.9M | -1.6% |
| FY2019 | $95.4M | +75.0% |
| FY2018 | $54.5M | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026